DreaMed Diabetes

Company Overview

Snapshot

Founded in March 2014 by Eran Atlas, Ido Mueller, Dr. Revital, Tadej Battelino, Thomas Danne, Moshe Phillip, Revital Nimri, and Ido Muller, DreaMed Diabetes operates with 11–50 employees. The company has raised a total of $16.8 million across 6 funding rounds from 5 investors. In August 2024, DreaMed Diabetes secured a funding round led by eHealth Ventures.

Business overview

DreaMed Diabetes develops decision-support tools for diabetes management, leveraging advanced AI and analytics to transform patient data into expert-level treatment recommendations. Its core product, endo.digital, is a cloud-based SaaS platform providing an end-to-end diabetes care pathway solution for healthcare organizations. The platform is cleared by the FDA to support both Type 1 and Type 2 diabetes, serving markets in Health Tech & Life Sciences, specifically Digital Healthcare and Medical Devices.

Strategic signal

In August 2024, DreaMed Diabetes secured a $3 million funding round led by eHealth Ventures. The company also signed strategic data integration agreements with Abbott and partnerships with health systems like Yale New Haven Health. This signals strong market validation for its AI-based endo.digital platform and indicates a significant push towards commercial expansion and broader adoption within the U.S. healthcare landscape.

Company Intelligence Q&A

What was a key recent funding event for DreaMed Diabetes?

In August 2024, DreaMed Diabetes raised $3 million in a funding round led by eHealth Ventures. This funding is intended to support the further commercialization of the company's AI-based platform, endo.digital.

What significant partnership did DreaMed Diabetes announce in June 2024?

In June 2024, DreaMed Diabetes announced that Abbott's FreeStyle Libre data now integrates into its endo.digital platform. This integration enhances the capabilities of DreaMed's AI-based decision support system by incorporating data from a leading continuous glucose monitoring device.

What was a notable achievement for DreaMed Diabetes in October 2023?

In October 2023, DreaMed Diabetes received its fifth FDA clearance. This regulatory milestone further validates the safety and efficacy of the company's decision support systems for diabetes management.

What was the outcome of the partnership with Yale New Haven Health in May 2024?

In May 2024, a case study with Yale New Haven Health demonstrated that DreaMed's EMR-integrated deployment freed up 9 minutes per patient visit. This highlights the operational efficiency and time-saving benefits of the endo.digital platform for healthcare providers.

What was the impact of the endo.digital platform on Billings Clinic's revenue in April 2024?

In April 2024, Billings Clinic's endocrinology department reported a 60% increase in CGM 95251 revenue with the endo.digital platform. This indicates the platform's positive financial impact and its ability to enhance service offerings for clinics.